Herbert Fritsche, Jr., Ph.D.

Dr. Herbert Fritsche, Advisor, is one of the world’s leading experts on tumor biomarkers.  He has recently worked extensively on laboratory test result reporting and interpretation, including pattern recognition, algorithms, and related software development, connected with personalized medicine in oncology.  Dr. Fritsche served as Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas until 2010.  During his 41 years at M.D. Anderson Cancer Center, Dr. Fritsche focused his research activities on the development and validation of cancer diagnostics.  He has been involved with the commercialization of every serum cancer biomarker product in use in the United States, and many of the new tissue based molecular markers.  Dr. Fritsche has served as President of the Clinical Ligand Assay Society (CLAS) and is a Fellow of the National Academy of Clinical Biochemistry.  He has served on the Expert Panel for Tumor Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO), the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, as a consultant/advisor to the National Cancer Institute (NCI) and the U.S. Food and Drug Administration (FDA).  He has also consulted with many major international diagnostic companies and biotech start-up companies.  Dr. Fritsche has published over 200 peer-reviewed scientific papers, invited articles and book chapters, holds three patents, and serves on the Editorial Board of six international scientific journals.

Dr. Fritsche holds a Ph.D. in Chemistry from Texas A&M University, and a B.S. in Chemistry from the University of Houston.